{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:20:28Z","timestamp":1788790828425,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Zafgen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Hypothalamic injury\u2010associated obesity (\n                      <jats:styled-content style=\"fixed-case\">HIAO<\/jats:styled-content>\n                      ) results from damage to the hypothalamus that often occurs with surgical removal\/radiation therapy of tumours in the hypothalamic region, such as craniopharyngioma. There is currently no rigorously studied pharmaceutical treatment for the intractable weight gain and cardiometabolic consequences that occur in patients with\n                      <jats:styled-content style=\"fixed-case\">HIAO<\/jats:styled-content>\n                      . We aimed to assess efficacy, safety and tolerability of beloranib treatment for 4 to 8\u2009weeks in patients with\n                      <jats:styled-content style=\"fixed-case\">HIAO<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This\n                      <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      hase 2a, double\u2010blind, placebo\u2010controlled study included 14 patients with\n                      <jats:styled-content style=\"fixed-case\">HIAO<\/jats:styled-content>\n                      , randomized to receive beloranib 1.8\u2009mg or placebo subcutaneously twice weekly for 4\u2009weeks with an optional 4\u2010week open\u2010label extension in which all patients received beloranib. The primary endpoint was change in weight from baseline to Week 4.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Participants were 64% female, with a mean (\n                      <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>\n                      ) age of 32 (9)\u2009years,\n                      <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\n                      of 43 (7)\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and weight of 126 (22)\u2009kg. Compared with placebo (N\u2009=\u20094), beloranib 1.8\u2009mg (N\u2009=\u20098) resulted in a mean (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ) difference in weight of \u22123.2 (\u22125.4, \u22120.9)\u2009kg after 4\u2009weeks. Weight loss continued through the 8\u2009weeks in patients randomized to beloranib (mean \u22126.2 [\u22128.2, \u22124.1]\u2009kg). Beloranib treatment was associated with improvements in high\u2010sensitivity\n                      <jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>\n                      . Adverse events were mild to moderate. No patients who received beloranib discontinued treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Beloranib treatment resulted in progressive weight loss in patients with\n                      <jats:styled-content style=\"fixed-case\">HIAO<\/jats:styled-content>\n                      that was comparable to that observed with beloranib in patients with exogenous obesity. These findings indicate a novel mechanism for treating obesity in patients with\n                      <jats:styled-content style=\"fixed-case\">HIAO<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12928","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T04:07:12Z","timestamp":1488773232000},"page":"1165-1170","source":"Crossref","is-referenced-by-count":33,"title":["A randomized, placebo\u2010controlled trial of beloranib for the treatment of hypothalamic injury\u2010associated obesity"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-3677","authenticated-orcid":false,"given":"Ashley","family":"Shoemaker","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology and Diabetes, Vanderbilt University Medical Center  Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Proietto","sequence":"additional","affiliation":[{"name":"Department of Medicine Austin Health, University of Melbourne  Heidelberg Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jennifer","family":"Abuzzahab","sequence":"additional","affiliation":[{"name":"McNeely Pediatric Diabetes Center and Endocrine Clinic, Children's Hospitals and Clinics of Minnesota  St. Paul Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Markovic","sequence":"additional","affiliation":[{"name":"Boden Institute of Nutrition, Exercise &amp; Eating Disorders University of Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaret","family":"Malloy","sequence":"additional","affiliation":[{"name":"Zafgen Inc.  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Kim","sequence":"additional","affiliation":[{"name":"Zafgen Inc.  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031751"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1115"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02196.x"},{"key":"e_1_2_6_5_1","first-page":"220","article-title":"Hypothalamic obesity: causes, consequences, treatment","volume":"6","author":"Lustig RH","year":"2008","journal-title":"Pediatr Endocrinol Rev"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-008-0096-4"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4184"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12031"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1677\/jme.1.02165"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12457"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162349799"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.08.046"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2007.10.009"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20356"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801083"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2001.13"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21538"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035622"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2227"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/clinchem\/48.6.877","article-title":"Effect of atorvastatin and fish oil on plasma high\u2010sensitivity C\u2010reactive protein concentrations in individuals with visceral obesity","volume":"48","author":"Chan DC","year":"2002","journal-title":"Clin Chem"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.05.043"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2206"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0124"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000115514.44135.A8"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128987"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318921"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi049172p"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00001"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.03993.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:39:43Z","timestamp":1761860383000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/dom.12928"],"URL":"https:\/\/doi.org\/10.1111\/dom.12928","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,18]]}}}